Efficacy and safety of ketamine for pediatric and adolescent super-refractory status epilepticus and the effect of cerebral inflammatory conditions.
J Neurol Sci
; 459: 122950, 2024 Apr 15.
Article
em En
| MEDLINE
| ID: mdl-38461760
ABSTRACT
OBJECTIVE:
To investigate the short-term benefits and adverse effects of ketamine in the treatment of pediatric and adolescent super-refractory status epilepticus (SRSE), with a focus on the inflammatory etiology.METHODS:
This retrospective observational cohort study included a consecutive series of 18 pediatric to adolescent patients with SRSE admitted between 2008 and 2023 and treated with ketamine. Seizure frequency per hour before and after ketamine administration and response rate were calculated. Neurological decline, catecholamine administration, and adverse effects were also assessed. The patients were divided into inflammatory and non-inflammatory etiology groups.RESULTS:
The median age at SRSE onset was 1 year 5 months (range 11 days-24 years), and 78% of the patients were male individuals. The median duration of treatment was 7.5 days (interquartile range 2.8-15.5 days). Fifteen (83%) patients achieved >50% seizure reduction. The median seizure frequency before and after ketamine treatment was 5.9 and 0.9, respectively, showing a significant reduction in seizure frequency (p < 0.0001). Ten patients had inflammatory etiologies including bacterial meningitis (n = 2), viral encephalitis (n = 3), and febrile infection related epilepsy syndrome (n = 5). The inflammatory etiology group required a longer treatment duration (p = 0.0453) and showed lower seizure reduction (p = 0.0264), lower response rate (p = 0.0044), and higher neurological decline (p = 0.0003) than the non-inflammatory etiology group. Three (17%) patients experienced transient adverse events requiring intervention within 24 h of initiating ketamine administration.CONCLUSIONS:
Ketamine administration was associated with fewer serious adverse events and a reduced seizure frequency. Additionally, inflammatory conditions may weaken the efficacy of ketamine in patients with SRSE.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Estado Epiléptico
/
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
/
Ketamina
/
Doenças Neuromusculares
Limite:
Adolescent
/
Child
/
Female
/
Humans
/
Male
/
Newborn
Idioma:
En
Revista:
J Neurol Sci
/
J. neurol. sci
/
Journal of the neurological sciences
Ano de publicação:
2024
Tipo de documento:
Article